Trial Profile
A combination trial of Ad-RTS-hIL-12 and immune checkpoint inhibitors in multiple tumor types
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2022
Price :
$35
*
At a glance
- Drugs INXN 2001 (Primary) ; Veledimex (Primary) ; Immunotherapies
- Indications Glioblastoma; Solid tumours
- Focus Adverse reactions
- 06 Jun 2018 New trial record
- 10 May 2018 According to a Ziopharm Oncology media release, the company expects to initiate this trial later this year.